Elizabeth Griffiths, MD

PrintE-mail
Staff Physician, Leukemia Service, Department of Medicine
Roswell Park Cancer Institute

Profile

Areas of Expertise: 
Acute lymphoblastic leukemia (ALL)
Acute myeloid leukemia (AML)
Chronic myeloid leukemia (CML)
Hematologic Oncology
Myelodysplastic syndrome (MDS)
Myeloproliferative diseases (MPD)

Research

Research Interests: 
Epigenetic changes in leukemia and myelodysplastic syndromes, novel therapeutics for elderly Acute Myeloid Leukemia

Background Information

Education and Training: 
University of North Carolina School of Medicine, Chapel Hill, NC
Residency: 
Johns Hopkins Hospital, Baltimore, MD
Board Certification: 
Hematology, American Board of Internal Medicine
Oncology, American Board of Internal Medicine
Internal Medicine, American Board of Internal Medicine
Fellowships: 
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Hospital, Baltimore, MD

Publications

Publications: 
  • Griffiths EA, Herman JG, Ye Y, Mohammad HP, Smith BD, Karp JE, McDevitt MA, Hooker C, Gore SD, Carraway HE. Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation. Leukemia and lymphoma 2010; 51(9):1711-1719
  • Bailey VJ , Keeley BP , Razavi CR , Griffiths E , Carraway HE , Wang T-H. DNA methylation detection using MS-qFRET, a quantum dot-based nanoassay. Methods (San Diego, Calif.) 2010; 52(3):237-241
  • Griffiths EA , Gore SD , Hooker CM , Mohammad HP , McDevitt MA , Smith BD , Karp JE , Herman JG , Carraway HE. Epigenetic differences in cytogenetically normal versus abnormal acute myeloid leukemia. Epigenetics 2010; 5(7):590-600
  • Lee HJ, Trump D, Johnson CS, Wang ES, Thompson JE, Griffiths EA, Vigil CE, Barcos M, Block A, Sait S, Ford LA, Wilding G, Wei T, Muindi J, Wetzler M. Subnormal vitamin D levels are associated with adverse outcome in newly-diagnosed similarly-treated adult acute myeloid leukemia (AML) patients. Blood 2010; 116(21):Abstract #1041
  • Vigil CE, Griffiths EA, Wang ES, Wetzler M. Interpretation of cytogenetic and molecular results in patients treated for CML. Blood reviews 2011; 25(3):139-146
  • Lee HJ, Wright KM, Kandeel E, Tan W, Wilding GE, Ford LA, Sait SN, Block AMW, Barcos MP, McCarthy PL, Vigil CE, Griffiths EA, Thompson JE, Wang ES, Wallace PK, Wetzler M. The role of minimal residual disease (MRD) by flow cytometry (FC) in predicting outcome in similarly treated acute lymphoblastic leukemia (ALL) patients : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):6592
  • Griffiths EA, Karpf AR, Odunsi K, James SR, Beck AF, Wetzler M, Ford LA. Conventional Dose Hypomethylating Agents Induce CG Antigen Genes In Vivo. Blood 2011; 118(21):1049
  • Vigil CE, Griffiths EA, Thompson JE, Tan W, Greene J, Ford LA, Wang ES, Wetzler M. A phase II study of clofarabine and daunorubicin in patients age 60 or older with newly diagnosed adult acute myeloid leukemia. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #6602
  • Sardesai SD, Tan W, Ford LA, Deeb G, Block AMW, Sait SNJ, McCarthy PL, Vigil CE, Griffiths EA, Thompson JE, Wang ES, Wallace PK, Wetzler M. Predicting outcome based on minimal residual disease (MRD) using multiparameter flow cytometry (FC) in acute myeloid leukemia (AML) patients (Pts) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #6565
  • Griffiths EA, Gore SD. Epigenetic therapies in MDS and AML. Advances in experimental medicine and biology 2013; 754 :253-283